Atrinositol | 28841-62-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Atrinositol
• 英文别名: [(1R,2S,4R,5R)-2,3,4-trihydroxy-5,6-diphosphonooxycyclohexyl] dihydrogen phosphate
• CAS: 28841-62-5
• 化学式: C₆H₁₅O₁₅P₃
• 分子量: 420.1
• InChiKey: GKDKOMAJZATYAY-GCVPSNMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  261
• 氢给体数：
  9
• 氢受体数：
  15

反应信息

• 作为产物：
  描述：

  植酸钠 、 sodium hydroxide 以 乙醇 为溶剂， 以The purified sodiumsalt of D-myo-inositol-1.2.6-triphosphate obtained的产率得到Atrinositol
  参考文献：
  名称：

  Inositoltriphosphate

  摘要：

  一种肌醇三磷酸(IP.sub.3)，所选自D-肌醇-1.2.6-三磷酸、D-肌醇-1.2.5-三磷酸、L-肌醇-1.3.4-三磷酸和肌醇-1.2.3-三磷酸组成的群组，以及生产该肌醇三磷酸的方法和包含该肌醇三磷酸的组合物。

  公开号：

  US04777134A1

文献信息

• Inositoltriphosphate
  申请人：——

  公开号：US04777134A1

  公开（公告）日：1988-10-11

  An inositoltriphosphate (IP.sub.3) selected from the group consisting of D-myo-inositol-1.2.6-triphosphate, D-myo-inositol-1.2.5-triphosphate, L-myo-inositol-1.3.4-triphosphate and myo-inositol-1.2.3-triphosphate, a method for producing the same and a composition comprised of the same.

  一种肌醇三磷酸(IP.sub.3)，所选自D-肌醇-1.2.6-三磷酸、D-肌醇-1.2.5-三磷酸、L-肌醇-1.3.4-三磷酸和肌醇-1.2.3-三磷酸组成的群组，以及生产该肌醇三磷酸的方法和包含该肌醇三磷酸的组合物。
• Inositol triphosphates
  申请人：——

  公开号：US04851560A1

  公开（公告）日：1989-07-25

  The disclosure of the present invention is directed to an inositol triphosphate compound, useful as a pharmaceutical agent, having the structural formula ##STR1## where (a) three of R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.10 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.8, R.sub.9 and R.sub.12 are hydrogen; (b) three of R.sub.1, R.sub.3, R.sub.6, R.sub.7, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.8, R.sub.10 and R.sub.11 are hydrogen; (c) three of R.sub.1, R.sub.3, R.sub.5, R.sub.8, R.sub.10 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.9 and R.sub.11 are hydrogen; (d) three or R.sub.1, R.sub.4, R.sub.5, R.sub.8, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.3, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen; (e) three of R.sub.1, R.sub.3, R.sub.6, R.sub.8, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.7, R.sub.10 and R.sub.11 are hydrogen; (f) three of R.sub.1, R.sub.3, R.sub.6, R.sub.7, R.sub.10 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.8, R.sub.9 and R.sub.11 are hydrogen; (g) three of R.sub.1, R.sub.3, R.sub.5, R.sub.8, R.sub.10 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.9 and R.sub.12 are hydrogen; or (h) three of R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.9 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.8, R.sub.10 and R.sub.12 are hydrogen.

  本发明的披露涉及一种肌醇三磷酸化合物，其具有以下结构式，可用作药物制剂：##STR1## 其中（a）R1、R3、R5、R7、R10和R11中的三个为羟基，其余三个为磷酸酯，R2、R4、R6、R8、R9和R12为氢；（b）R1、R3、R6、R7、R9和R12中的三个为羟基，其余三个为磷酸酯，R2、R4、R5、R8、R10和R11为氢；（c）R1、R3、R5、R8、R10和R12中的三个为羟基，其余三个为磷酸酯，R2、R4、R6、R7、R9和R11为氢；（d）R1、R4、R5、R8、R9和R12中的三个为羟基，其余三个为磷酸酯，R2、R3、R6、R7、R10和R11为氢；（e）R1、R3、R6、R8、R9和R12中的三个为羟基，其余三个为磷酸酯，R2、R4、R5、R7、R10和R11为氢；（f）R1、R3、R6、R7、R10和R12中的三个为羟基，其余三个为磷酸酯，R2、R4、R5、R8、R9和R11为氢；（g）R1、R3、R5、R8、R10和R11中的三个为羟基，其余三个为磷酸酯，R2、R4、R6、R7、R9和R12为氢；或（h）R1、R3、R5、R7、R9和R11中的三个为羟基，其余三个为磷酸酯，R2、R4、R6、R8、R10和R12为氢。